We found that the difference seen in the severe maternal adverse outcome composite was most marked in the PlGF 12–100 pg/ml group (aOR 0.15 (95% CI 0.03 to 0.92) and we anticipate that this may offer clinicians an opportunity to identify women at risk of developing severe preeclampsia complications, who may otherwise be considered at lower risk. Here, PGF is linked to preeclampsia.